Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 2(4)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05244993Phase 2Unknown

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Role: collaborator

NCT05426811Phase 1Unknown

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Role: collaborator

NCT04612673Phase 2Unknown

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Role: collaborator

NCT03116555Phase 2Unknown

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Role: collaborator

NCT03732001Phase 2Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC

Role: collaborator

NCT02203253Phase 3Completed

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

Role: collaborator

All 6 trials loaded